Inhibition of Akt pathways in the treatment of prostate cancer

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Akt is a serine/threonine kinase mediating multiple intracellular pathways involved in prostate cancer (CaP) biology. Increased understanding of the molecular mechanisms of Akt activation and signaling have led to the development of an increasing number of Akt inhibitors. These biologic agents demonstrate activity against a wide range of cancers in preclinical studies. Clinical studies of Akt inhibition in CaP are in progress, including agents such as celecoxib, perifosine and genistein. How best to integrate Akt inhibitors with standard CaP therapy or select patients most likely to benefit is the subject of ongoing research.

Original languageEnglish (US)
Pages (from-to)331-339
Number of pages9
JournalProstate Cancer and Prostatic Diseases
Issue number4
StatePublished - Dec 2007

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Inhibition of Akt pathways in the treatment of prostate cancer'. Together they form a unique fingerprint.

Cite this